Medicinal carbohydrates for treatment of respiratory conditions

A method of treating a respiratory condition resulting from a damaged respiratory cell in a subject post a viral or bacterial respiratory infection, the method including a step of administering to the subject post a viral or bacterial respiratory infection an effective amount of at least one pharmaceutically acceptable compound that accelerates sialylglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of a respiratory cell in the subject to promote recovery of cell viability of a damaged respiratory cell, wherein the subject suffers from a respiratory condition selected from the group consisting of cough, acute bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, and cystic fibrosis and wherein the at least one pharmaceutically acceptable compound is selected from the group consisting of compounds of Formula (1) and compounds of Formula (2) wherein Formula (1) has the formula:

• wherein,
• R1, R2, R3, are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2Ph, COCR5R6R7, and CO-active esters;
• R5, R6, R7 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), C6H5, CH2Ph, and CH3CH2(OCH2CH2)mCH3 (m=1-200);
• R4 is the same or different to R1, R2, R3 and is selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2Ph, COCR5R6R7, CO-active esters and
• R5′, R6′ are the same or different and are each independently selected from the group consisting of H or a pharmaceutically suitable inorganic or organic salt, and a pharmaceutically suitable ester;
• one of A and B is H, with the proviso that:
• when B is H, then A is selected from the group consisting of NHCOCH3, NH2, OH, and NH2.HX or
• when A is H, B is selected from the group consisting of NH2 and NH2.HX, wherein HX represents a pharmaceutically suitable inorganic or organic acid;
• and
• wherein Formula (2) has the formula
• wherein,
• R8 is selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2Ph, COCH2Ph, CO-active ester and COCR14R15R16;
• wherein R14, R15, R16 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), C6H5, CH2Ph, CH2CH2(OCH2CH2)mCH3 (m=1-200), cytidine, cytidine monophosphate, cytidine diphosphate, cytidine triphosphate, adenosine, adenosine monophosphate, adenosine diphosphate, and adenosine triphosphate;
• R9 is selected from the group consisting of H, CH3, a pharmaceutically acceptable inorganic or organic salt, a pharmaceutically suitable active ester, and CH2CR17R18R19, wherein R17, R18, R19 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2CH2(OCH2CH2)mCH3 (m=1-200), C6H5, and CH2Ph;
• R10, R11, R12 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2Ph, active ester, and COCR20R21R22, wherein R20, R21, and R22 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), C6H5, CH2Ph, and CH2CH2(OCH2CH2)mCH3 (m=1-200);
• R13 is the same or different from R10, R11, R12 and is selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2Ph, active ester, and COCR20R21R22, wherein R20, R21, and R22 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), C6H5, CH2Ph, CH2CH2(OCH2CH2)mCH3 (m=1-200) and
• R23, R24 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), CH2CH2(OCH2CH2)mCH3 (m=1-200), CH2Ph, or active ester, and CH2CR25R26R27, or pharmaceutically acceptable inorganic or organic salt, and R25, R26, R27 are the same or different and are each independently selected from the group consisting of H, CH3, (CH2)nCH3 (n=1-20), C6H5, and CH2Ph.